Nialamide

Nialamide
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	N06AF02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only);
Identifiers
	IUPAC name N-benzyl-3-(N-(pyridine-4-carbonyl)hydrazino)propanamide;
CAS Number	51-12-7 ;
PubChem CID	4472;
DrugBank	DB04820 ;
ChemSpider	4317 ;
UNII	T2Q0RYM725;
KEGG	D07337 ;
CompTox Dashboard (EPA)	DTXSID1023362 ;
ECHA InfoCard	100.000.073
Chemical and physical data
Formula	C16H18N4O2
Molar mass	298.346 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NNCCC(=O)NCc1ccccc1)c2ccncc2;
	InChI InChI=1S/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22) ; Key:NOIIUHRQUVNIDD-UHFFFAOYSA-N ;
	(verify)

Nialamide (Niamid, Niamide, Nuredal, Surgex) is a non-selective, irreversible monoamine oxidase inhibitor (MAOI) of the hydrazine class that was used as an antidepressant.^[1] It was withdrawn by Pfizer several decades ago due to the risk of hepatotoxicity.^[2]^[3]

The antiatherogenic activity of nialamide was used to design pyridinolcarbamate.^[4]

References

^ William Andrew Publishing (1 December 2006). Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. Elsevier. pp. 2935–. ISBN 978-0-8155-1856-3.
^ Shayne C. Gad (26 April 2012). Safety Pharmacology in Pharmaceutical Development: Approval and Post Marketing Surveillance, Second Edition. CRC Press. pp. 138–. ISBN 978-1-4398-4567-7.
^ Edward Shorter (28 September 2008). Before Prozac : The Troubled History of Mood Disorders in Psychiatry: The Troubled History of Mood Disorders in Psychiatry. Oxford University Press. pp. 137–. ISBN 978-0-19-970933-5.
^ Bencze, W. L.; Dempsey, M. E.; Eisenberg, S.; Felts, J. M.; Frantz, I. D.; Hess, R.; Levy, R. I.; Miettinen, T. A.; Rudel, L. L.; Sodhi, H. S.; Stäubli, W.; Zemplényi, T. (6 December 2012). "Hypolipidemic Agents". Springer Science & Business Media. Retrieved 3 October 2017 – via Google Books.